Federico Innocenti

Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma

Adrian Ally, Miruna Balasundaram, Rebecca Carlsen et al. · Cell · 2017 · 2.5K citations · Full text

Genetic Variants in the <i>UDP-glucuronosyltransferase 1A1</i> Gene Predict the Risk of Severe Neutropenia of Irinotecan

Federico Innocenti, Samir D. Undevia, Lalitha Iyer et al. · Journal of Clinical Oncology · 2004 · 946 citations · Full text

Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With <i>KRAS</i> Wild-Type Advanced or Metastatic Colorectal Cancer

Alan P. Venook, Donna Niedzwiecki, Heinz‐Josef Lenz et al. · JAMA · 2017 · 852 citations · Full text

Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)

Hedy L. Kindler, Donna Niedzwiecki, Donna Hollis et al. · Journal of Clinical Oncology · 2010 · 837 citations · Full text

CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC).

Alan P. Venook, Donna Niedzwiecki, Heinz‐Josef Lenz et al. · Journal of Clinical Oncology · 2014 · 403 citations

Calgb/swog 80405, Kras Wild-type, Lba3 Background +15